China-based Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) has announced that its wholly owned subsidiary, Techdow USA Inc., has entered into a distribution and supply agreement with compatriot firm Chia Tai Tianqing. The agreement centers on Chia Tai Tianqing’s ANDA-approved fosaprepitant dimeglutide in the United States, with Techdow being awarded commercialization rights to the drug in the US market.
Commercialization Rights and Royalty Agreement
Under the terms of the agreement, Techdow will procure the drug at a certain price from Chia Tai and will provide a royalty on net profits. While other financial specifics of the deal were not disclosed, this partnership highlights the strategic expansion of both companies in the US pharmaceutical market.
Fosaprepitant Dimeglutide: A Neurokinin 1 (NK-1) Antagonist
Fosaprepitant dimeglutide is a neurokinin 1 (NK-1) antagonist used to prevent nausea and vomiting caused by chemotherapy. Chia Tai’s version of the drug received marketing approval in the US in March 2021, following approvals in the European Union and China. The drug’s approval and subsequent distribution in the US market underscore its potential to provide relief to patients undergoing chemotherapy and further solidify the partnership between Shenzhen Hepalink’s subsidiary and Chia Tai Tianqing.-Fineline Info & Tech
